Heterogeneity in transmissibility and shedding
SARS-CoV-2 via droplets and aerosols

Paul Z. Chen[a], Niklas Bobrovitz[b-d], Zahra Premji[e], Marion Koopmans[f], David N. Fisman[g,h],

Frank X. Gu[a,i,1]

Affiliations:

[a]Department of Chemical Engineering & Applied Chemistry, University of Toronto, Toronto,

Canada

[b]Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

[c]Department of Critical Care Medicine, Cumming School of Medicine, University of Calgary,

Calgary, Canada

[d]O'Brien Institute of Public Health, University of Calgary, Calgary, Canada

[e]Libraries & Cultural Resources, University of Calgary, Calgary, Canada

[f]Department of Viroscience, Erasmus University Medical Center, Rotterdam, Netherlands

[g]Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto,

Canada

[h]Division of Infectious Diseases, Temerty Faculty of Medicine, University of Toronto, Toronto,

Canada

[i]Institute of Biomedical Engineering, University of Toronto, Toronto, Canada

[1]To whom correspondence may be addressed: Frank X. Gu.

Email: f.gu@utoronto.ca

Abstract

Which virological factors mediate overdispersion in the transmissibility of emerging viruses remains a longstanding question in infectious disease epidemiology. Here, we use systematic review to develop a comprehensive dataset of respiratory viral loads (rVLs) of SARS-CoV-2, SARS-CoV-1 and influenza A(H1N1)pdm09. We then comparatively meta-analyze the data and model individual infectiousness by shedding viable virus via respiratory droplets and aerosols. Our analyses indicate heterogeneity in rVL as an intrinsic virological factor facilitating greater overdispersion for SARS-CoV-2 in the COVID-19 pandemic than A(H1N1)pdm09 in the 2009 influenza pandemic. For COVID-19, case heterogeneity remains broad throughout the infectious period, including for pediatric and asymptomatic infections. Hence, many COVID-19 cases inherently present minimal transmission risk, whereas highly infectious individuals shed tens to thousands of SARS-CoV-2 virions/min via droplets and aerosols while breathing, talking and singing. Coughing increases the contagiousness, especially in close contact, of symptomatic cases relative to asymptomatic ones. Infectiousness tends to be elevated between 1-5 days post-symptom onset. Our findings show how individual case variations influence virus transmissibility and present considerations for disease control in the COVID-19 pandemic.

Significance Statement

For some emerging infectious diseases, including COVID-19, few cases cause most secondary infections. Others, like influenza A(H1N1)pdm09, spread more homogenously. The virological factors that mediate such distinctions in transmissibility remain unelucidated, prohibiting the development of specific disease control measures. We find that intrinsic case variation in respiratory viral load (rVL) facilitates overdispersion, and superspreading, for COVID-19 but

more homogeneous transmission for A(H1N1)pdm09. We interpret the influence of

heterogeneity in rVL on individual infectiousness by modelling likelihoods of shedding viable

virus via respiratory droplets and aerosols. We analyze the distribution and kinetics of SARS-

CoV-2 rVL, including across age and symptomatology subgroups. Our findings compare

individual infectiousness across COVID-19 and A(H1N1)pdm09 cases and present quantitative

guidance on triaging COVID-19 contact tracing.

Main Text

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing

the coronavirus disease 2019 (COVID-19) pandemic with more than 62.5 million infections and

1.4 million deaths (as of 29 November 2020) (1). For respiratory virus transmission, airway

epithelial cells shed virions to the extracellular fluid before atomization (from breathing, talking,

singing, coughing and aerosol-generating procedures) partitions them into a polydisperse mixture

of particles that are expelled to the ambient environment. Aerosols ($\leq$100 μm) can be inhaled

nasally, whereas droplets (>100 μm) tend to be excluded (2, 3). For direct transmission, droplets

must be sprayed ballistically onto susceptible tissue (4). Hence, droplets predominantly deposit

on nearby surfaces, potentiating indirect transmission. Aerosols can be further categorized based

on typical travel characteristics: short-range aerosols (50-100 μm) tend to settle within 2 m; long-

range ones (10-50 μm) often travel beyond 2 m based on emission force; and buoyant aerosols

($\leq$10 μm) remain suspended and travel based on airflow profiles for minutes to many hours (4,

5). Although proximity has been associated with infection risk for COVID-19 (6), studies have

also suggested that long-range airborne transmission occurs conditionally (7-9).

While the basic reproductive number has been estimated to be 2.0-3.6 (10, 11),

transmissibility of SARS-CoV-2 is highly overdispersed (dispersion parameter k, 0.10-0.58),

with numerous instances of superspreading (7-9) and few cases (10-20%) causing many

secondary infections (80%) (12-14). Similarly, few cases drive the transmission of SARS-CoV-1

(k, 0.16-0.17) (15), whereas influenza A(H1N1)pdm09 transmits more homogeneously (k, 7.4-

14.4) (16, 17), despite both viruses spreading by contact, droplets and aerosols (18, 19).

Although understanding the determinants of viral overdispersion is crucial towards

characterizing transmissibility and developing effective strategies to limit infection (20),

mechanistic associations for k remain unclear. As an empirical estimate, k depends on myriad

extrinsic (behavioral, environmental and invention) and host factors. Nonetheless, k remains

similar across distinct outbreaks (15), suggesting that intrinsic virological factors mediate

overdispersion for emerging viruses.

Here, we investigated how intrinsic case variation in rVL facilitates overdispersion in

SARS-CoV-2 transmissibility. By systematic review, we developed a comprehensive dataset of

rVLs from cases of COVID-19, SARS and A(H1N1)pdm09. Using comparative meta-analyses,

we found that heterogeneity in rVL was associated with overdispersion among these emerging

infections. To assess potential sources of case heterogeneity, we analyzed SARS-CoV-2 rVLs

across age and symptomatology subgroups as well as disease course. To interpret the influence

of heterogeneity in rVL on individual infectiousness, we modelled likelihoods of shedding viable

virus via respiratory droplets and aerosols.

Results

Systematic review

We conducted a systematic review on virus quantitation in respiratory specimens taken during

the infectious periods of SARS-CoV-2 (-3 to 10 days from symptom onset [DFSO]) (21-23),

SARS-CoV-1 (0-20 DFSO) (24) and A(H1N1)pdm09 (-2 to 9 DFSO) (25) (Methods). The

systematic search (*SI Appendix*, Tables S1 to S5) identified 4,274 results. After screening and

full-text review, 64 studies met the inclusion criteria and contributed to the systematic dataset

(Fig. 1) ($N = 9,631$ total specimens), which included adult ($N = 5,033$) and pediatric ($N = 1,608$)

cases from 15 countries and specimen measurements for asymptomatic ($N = 2,387$),

presymptomatic ($N = 28$) and symptomatic ($N = 7,161$) infections. According to a hybrid Joanna

Briggs Institute critical appraisal checklist, risk of bias was low for most contributing studies (*SI*

Appendix, Table S6).

Association of overdispersion with heterogeneity in rVL

We hypothesized that individual case variation in rVL facilitates the distinctions in k among

COVID-19, SARS and A(H1N1)pdm09. For each study in the systematic dataset, we used

specimen measurements (viral RNA concentration in a respiratory specimen) to estimate rVLs

(viral RNA concentration in the respiratory tract) (Methods). To investigate the relationship

between k and heterogeneity in rVL, we performed a meta-regression using each contributing

study (*SI Appendix*, Fig. S1), which showed a weak, negative association between the two

variables (meta-regression slope *t*-test: $P = 0.038$, Pearson's $r = -0.26$).

Using contributing studies with low risk of bias, meta-regression (Fig. 2) showed a strong,

negative association between k and heterogeneity in rVL (meta-regression slope *t*-test: $P < 10^{-9}$,

Pearson's $r = -0.73$). In this case, each unit increase (1 $\log_{10}$ copies/ml) in the standard deviation

(SD) of rVL decreased $\log(k)$ by a factor of -1.41 (95% confidence interval [CI]: -1.78 to -1.03),

suggesting that broader heterogeneity in rVL facilitates greater overdispersion in the

transmissibility of SARS-CoV-2 than of A(H1N1)pmd09. To investigate mechanistic aspects of

this association, we conducted a series of analyses on rVL and then modelled the influence of

heterogeneity in rVL on individual infectiousness.

Meta-analysis and subgroup analyses of rVL

We first compared rVLs among the emerging infections. We performed a random-effects meta-

analysis (*SI Appendix*, Fig. S2), which assessed the expected rVL when encountering a COVID-

19, SARS or A(H1N1)pdm09 case during the infectious period. This showed that the expected

rVL of SARS-CoV-2 was comparable to that of SARS-CoV-1 (one-sided Welch's *t*-test: $P =$

0.111) but lesser than that of A(H1N1)pdm09 ($P = 0.040$). We also performed random-effects

subgroup analyses for COVID-19 (Fig. 3), which showed that expected SARS-CoV-2 rVLs were

similar between pediatric and adult cases ($P = 0.476$) and comparable between

symptomatic/presymptomatic and asymptomatic infections ($P = 0.090$). Since these meta-

analyses had significant between-study heterogeneity among the mean estimates (Cochran's Q

test: $P < 0.001$ for each meta-analysis), we conducted risk-of-bias sensitivity analyses; meta-

analyses of low-risk-of-bias studies continued to show significant heterogeneity (*SI Appendix*,

Figs. S3 to S7).

Distributions of rVL

We next analyzed rVL distributions. For all three viruses, rVLs best conformed to Weibull

distributions (*SI Appendix*, Fig. S8), and we fitted the entirety of individual sample data for each

virus in the systematic dataset (Fig. 4*A* and *SI Appendix*, Fig. S8*N*). While COVID-19 and SARS

cases tended to shed lesser virus than those with A(H1N1)pdm09 (*SI Appendix*, Fig. S2), broad

heterogeneity in SARS-CoV-2 and SARS-CoV-1 rVLs inverted this relationship for highly

infectious individuals (Fig. 4*A* and *SI Appendix*, Fig. S9 *A* to *C*). At the 90th case percentile (cp)

throughout the infectious period, the estimated rVL was 8.91 (95% CI: 8.83-9.00) $\log_{10}$

copies/ml for SARS-CoV-2, whereas it was 8.62 (8.47-8.76) $\log_{10}$ copies/ml for A(H1N1)pdm09

(*SI Appendix*, Table S7). The SD of the overall rVL distribution for SARS-CoV-2 was 2.04 $\log_{10}$

copies/ml, while it was 1.45 $\log_{10}$ copies/ml for A(H1N1)pdm09, showing that heterogeneity in

rVL was indeed broader for SARS-CoV-2.

To assess potential sources of heterogeneity in SARS-CoV-2 rVL, we compared rVL

distributions among COVID-19 subgroups. In addition to comparable mean estimates (Fig. 3),

adult, pediatric, symptomatic/presymptomatic and asymptomatic COVID-19 cases showed

similar rVL distributions (Fig. 4 *B* and *C*), with SDs of 2.03, 2.06, 2.00 and 2.01 $\log_{10}$ copies/ml,

respectively. Thus, age and symptomatology minimally influenced case variation in SARS-CoV-

2 rVL during the infectious period.

SARS-CoV-2 kinetics during respiratory infection

To analyze the influences of disease course, we delineated individual SARS-CoV-2 rVLs by

DFSO and fitted the mean estimates to a mechanistic model for respiratory virus kinetics (Fig.

4*D* and Methods). The outputs indicated that, on average, each productively infected cell in the

airway epithelium shed SARS-CoV-2 at 1.33 (95% CI: 0.74-1.93) copies/ml day^{-1} and infected

up to 9.25 susceptible cells (*SI Appendix*, Table S8). The turnover rate for infected epithelial

cells was 0.71 (0.26-1.15) days^{-1}, while the half-life of SARS-CoV-2 in the respiratory tract was

5.04 (2.62-66.0) hours. By extrapolating the model to an initial rVL of 0 $\log_{10}$ copies/ml, the

estimated incubation period was 5.38 days, which agrees with epidemiological findings (10).

Conversely, the expected duration of shedding was 25.1 DFSO. Thus, SARS-CoV-2 rVL

increased exponentially after infection, peaked around 1 DFSO along with the proportion of

infected epithelial cells (*SI Appendix*, Fig. S10) and then diminished exponentially.

To evaluate case heterogeneity across the infectious period, we fitted distributions for each

DFSO (Fig. 4*E*), which showed that high SARS-CoV-2 rVLs also increased from the

presymptomatic period, peaked at 1 DFSO and then decreased towards the end of the first week

of illness. For the 90th cp at 1 DFSO, the rVL was 9.84 (95% CI: 9.17-10.56) $\log_{10}$ copies/ml, an

order of magnitude greater than the overall 90th-cp estimate. High rVLs between 1-5 DFSO were

elevated above the expected values from the overall rVL distribution (*SI Appendix*, Table S7). At

-1 DFSO, the 90th-cp rVL was 8.30 (6.88-10.02) $\log_{10}$ copies/ml, while it was 7.93 (7.35-8.56)

$\log_{10}$ copies/ml at 10 DFSO. Moreover, heterogeneity in rVL remained broad across the

infectious period, with SDs of 1.83-2.44 $\log_{10}$ copies/ml between -1 to 10 DFSO (*SI Appendix*,

Fig. S9 *H* to *S*).

Likelihood that droplets and aerosols contain virions

Towards analyzing the influence of heterogeneity in rVL on individual infectiousness, we first

modelled the likelihood of respiratory particles containing viable SARS-CoV-2. Since rVL is an

intensive quantity, the volume fraction of virions is low and viral partitioning coincides with

atomization, we used Poisson statistics to model likelihood profiles. To calculate an unbiased

estimator of partitioning (the expected number of viable copies per particle), our method

multiplied rVL estimates with particle volumes during atomization and an assumed viability

proportion of 0.1% in equilibrated particles (Methods).

When expelled by the mean COVID-19 case during the infectious period, respiratory

particles showed low likelihoods of carrying viable SARS-CoV-2 (*SI Appendix*, Fig. S11*B*).

Aerosols (equilibrium aerodynamic diameter [d_a] ≤ 100 μm) were ≤0.69% (95% CI: 0.43-0.95%)

likely to contain a virion. Droplets also had low likelihoods: at d_a = 330 μm, they were 19.4%

(18.5-20.3%), 2.42% (2.15-2.69%) and 0.20% (0.16-0.24%) likely to contain one, two or three

virions, respectively.

COVID-19 cases with high rVLs, however, expelled particles with considerably greater

likelihoods of carrying viable copies (Fig. 5 *A* and *B* and *SI Appendix*, Fig. S11 *D* and *E*). For the

80th cp during the infectious period, aerosols (d_a ≤ 100 μm) were ≤36.6% (95% CI: 35.3-38.0%)

likely to carry at least one SARS-CoV-2 virion. For the 90th cp, this likelihood was ≤96.7%

(96.5-96.9%), with larger aerosols tending to contain multiple virions (*SI Appendix*, Fig. S11*E*).

At 1 DFSO, these estimates were greatest, and ≤61.1% (51.8-70.4%) of buoyant aerosols (d_a ≤

10 μm) contained at least one viable copy of SARS-CoV-2 for the 98th cp. When expelled by

high cps, droplets (d_a > 100 μm) tended to contain tens to thousands of SARS-CoV-2 virions

(Fig. 5*B* and *SI Appendix*, Fig. S11*E*).

Shedding SARS-CoV-2 via respiratory droplets and aerosols

Using the partitioning estimates in conjunction with published profiles of the particles expelled

by respiratory activities (*SI Appendix*, Fig. S12), we next modelled the rates at which talking,

singing, breathing and coughing shed viable SARS-CoV-2 across d_a (Fig. 5 *C* to *F*). Singing

shed virions more rapidly than talking based on the increased emission of aerosols. Voice

amplitude, however, had a significant effect on aerosol production, and talking loudly emitted

aerosols at similar rates to singing (*SI Appendix*, Fig. S12*E*). Based on the generation of larger

aerosols and droplets, talking and singing shed virions more rapidly than breathing (Fig. 5 *C* to

E). Each cough shed similar quantities of virions as in a minute of talking (Fig. 5 *C* and *F*).

Each of these respiratory activities expelled aerosols at greater rates than droplets, but

particle size correlated with the likelihood of containing virions. Talking, singing and coughing

expelled virions at greater proportions via droplets (80.6-86.0%) than aerosols (14.0-19.4%)

(Fig. 5*G*). Moreover, short-range aerosols predominantly mediated the virions (90.8-92.6%) shed

via aerosols while talking normally and coughing. In comparison, while singing, talking loudly

and breathing, buoyant (29.7-68.4%) and long-range (10.3-31.6%) aerosols carried a larger

proportion of the virions shed via aerosols (Fig. 5*G*).

Influence of heterogeneity in rVL on individual infectiousness

To interpret how heterogeneity in rVL influences individual infectiousness, we modelled total

SARS-CoV-2 shedding rates (over all particle sizes) for each respiratory activity (Fig. 5*H* and *SI*

Appendix, Fig. S13). Between the 1st and the 99th cps, the estimates for a respiratory activity

spanned ≥8.48 orders of magnitude on each DFSO; cumulatively from -1 to 10 DFSO, they

spanned 11.0 orders of magnitude. Hence, many COVID-19 cases inherently presented minimal

transmission risk, whereas highly infectious individuals shed considerable quantities of SARS-

CoV-2. For the 98th cp at 1 DFSO, singing expelled 313 (95% CI: 37.5-3,158) virions/min to the

ambient environment, talking emitted 293 (35.1-2,664) virions/min, breathing exhaled 1.54

(0.18-15.5) virions/min and coughing discharged 249 (29.8-2,5111) virions/cough; these

estimates were approximately two orders of magnitude greater than those for the 85th cp. For the

98th cp at -1 DFSO, singing shed 14.5 (0.15-4,515) virions/min and breathing exhaled 7.13×10^{-2}

$(7.20\times10^{-4}$-22.2) virions/min. The estimates at 9-10 DFSO were similar to these presymptomatic

ones (Fig. 5*H* and *SI Appendix*, Fig. S13*B*). As indicated by comparable mean rVLs (Fig. 3) and

heterogeneities in rVL (Fig. 4 *B* and *C*), adult, pediatric, symptomatic/presymptomatic and

asymptomatic COVID-19 subgroups presented similar distributions for shedding virions through

these activities.

We also compared the influence of case variation on individual infectiousness between

A(H1N1)pdm09 and COVID-19. Aerosol spread accounted for approximately half of

A(H1N1)pdm09 transmission events (19), and the 50% human infectious dose for aerosolized

influenza A virus is approximately 1-3 virions in the absence of neutralizing antibodies (26).

Based on the model, 62.9% of A(H1N1)pdm09 cases were infectious (shed ≥1 virion) via

aerosols within 24 h of talking loudly or singing (*SI Appendix*, Fig. S14*A*). The estimate was

58.6% within 24 h of talking normally and 22.3% within 24 h of breathing. In comparison,

48.0% of COVID-19 cases shed ≥1 virion via aerosols in 24 h of talking loudly or singing (*SI*

Appendix, Fig. S14*C*). Notably, only 61.4% of COVID-19 cases shed ≥1 virion via either

droplets or aerosols in 24 h of talking loudly or singing (*SI Appendix*, Fig. S14*D*). While the

human infectious dose of SARS-CoV-2 by any exposure route remains unelucidated, it must be

at least one viable copy. Thus, at least 38.6% of COVID-19 cases were expected to present

negligible risk to spread SARS-CoV-2 through either droplets or aerosols in 24 h. The proportion

of inherently infectious cases further decreased as the infectious dose increased: 55.8, 42.5 and

25.0% of COVID-19 cases were expected to shed ≥2, ≥10 and ≥100 virions, respectively, in 24 h

of talking loudly or singing during the infectious period.

While these analyses indicated that a greater proportion of A(H1N1)pdm09 cases were

inherently infectious, 18.8% of COVID-19 cases shed virions more rapidly than those infected

with A(H1N1)pdm09 (Fig. 4*A*). At the 98th cp for A(H1N1)pdm09, singing expelled 4.38 (2.85-

6.78) virions/min and breathing exhaled 2.15×10^{-2} (1.40×10^{-2}-3.34×10^{-2}) virions/min. Highly

infectious COVID-19 cases expelled virions at rates that were up to 1-2 orders of magnitude

greater than their A(H1N1)pdm09 counterparts (Fig. 5*H* and *SI Appendix*, Fig. S15).

Discussion

This study provided systematic analyses of several factors characterizing SARS-CoV-2

transmissibility. First, we found that broader heterogeneity in rVL facilitates greater

overdispersion for SARS-CoV-2 than A(H1N1)pdm09. Our results suggest that many COVID-

19 cases infect no one (12-14) because they inherently present minimal transmission risk via

droplets or aerosols, although behavioral and environmental factors can further abate risk.

Meanwhile, highly infectious cases can shed tens to thousands of SARS-CoV-2 virions/min,

especially between 1-5 DFSO. The model estimates, when corrected to copies rather than

virions, align with recent clinical findings for exhalation rates of SARS-CoV-2 (27). In

comparison, a greater proportion of A(H1N1)pdm09 cases are infectious but shed virions at low

rates, which concurs with more uniform transmission and few superspreading events observed

during the 2009 H1N1 pandemic (16, 17). Moreover, our analyses suggest that heterogeneity in

rVL may be generally associated with overdispersion for viral respiratory infections. In this case,

rVL distribution can serve as an early correlate for transmission patterns, including

superspreading, during outbreaks of novel respiratory viruses, providing insight for disease

control before large-scale epidemiological studies empirically characterize *k*. When transmission

is highly overdispersed, targeted interventions may disproportionately mitigate infection (20),

with models estimating that focusing half of control efforts on the most infectious 20% of cases

outperforms random control policies threefold (15).

Second, we analyzed SARS-CoV-2 kinetics during respiratory infection. While

heterogeneity remains broad throughout the infectious period, rVL tends to peak at 1 DFSO and

be elevated for 1-5 DFSO, coinciding with the period of highest attack rates observed among

close contacts (28). These results indicate that transmission risk tends to be greatest soon after

illness rather than in the presymptomatic period, which concurs with large tracing studies (6.4-

12.6% of secondary infections from presymptomatic transmission) (29, 30) rather than early

temporal models (~44%) (23). Furthermore, our kinetic analysis suggests that, on average,

SARS-CoV-2 reaches diagnostic concentrations 1.54-3.17 days after respiratory infection (-3.84

to -2.21 DFSO), assuming assay detection limits of 1-3 $\log_{10}$ copies/ml, respectively, for

nasopharyngeal swabs immersed in 1 ml of transport media.

Third, we assessed the relative infectiousness of COVID-19 subgroups. As a common

symptom of COVID-19 (31), coughing sheds considerable numbers of virions via droplets and

short-range aerosols. Thus, symptomatic infections tend to be more contagious than

asymptomatic ones, providing one reason as to why asymptomatic cases transmit SARS-CoV-2

at lower relative rates (32), especially in close contact (33), despite similar rVLs and increased

contact patterns. Accordingly, children (48-54% of symptomatic cases present with cough) (34,

35) tend to be less contagious than adults (68-80%) (31, 35) based on tendencies of

symptomatology rather than rVL. Conversely, coughing sheds few virions via smaller aerosols.

Our analyses suggest that asymptomatic and symptomatic infections present comparable risks for

airborne spread, as do adult and pediatric cases. While singing and talking loudly, highly

infectious cases shed tens to hundreds of SARS-CoV-2 virions/min via long-range and buoyant

aerosols.

Our study has limitations. The systematic search found a limited number of studies reporting

quantitative specimen measurements from the presymptomatic period, meaning these estimates

may be sensitive to sampling bias. Although additional studies have reported semiquantitative

metrics (cycle thresholds), these data were excluded because they cannot be compared on an

absolute scale due to batch effects (36), limiting use in compound analyses. Furthermore, this

study considered population-level estimates of the infectious periods, viability proportions and

rate profiles for respiratory particles, which omit individual or environmental variation.

Distinctions in phonetic tendencies and, especially for young children, respiratory capacity lead

to variation in particle emission rates (37). Some patients shed SARS-CoV-2 with diminishing

viability soon after symptom onset (21), whereas others produce replication-competent virus for

weeks (38). It remains unclear how case characteristics and environmental factors affect the

viability dynamics of SARS-CoV-2.

Taken together, our findings provide a potential path forward for disease control. They

support aerosol spread as a transmission mode for SARS-CoV-2, including for conditional

superspreading by highly infectious cases. However, with short durations of stay in well-

ventilated areas, the exposure risk for aerosols, including long-range and buoyant ones, remains

correlated with proximity to infectious cases (2, 4). Strategies to abate infection should limit

crowd numbers and duration of stay while reinforcing distancing, low voice amplitudes and

widespread mask usage; well-ventilated settings can be recognized as lower risk venues.

Coughing can shed considerable quantities of virions, while rVL tends to peak at 1 DFSO and

can be high throughout the infectious period. Thus, immediate, sustained self-isolation upon

illness is crucial to curb transmission from symptomatic cases. Collectively, our analyses

highlight the role of cases with high rVLs in propelling the COVID-19 pandemic. While

diagnosing COVID-19, qRT-PCR can also triage contact tracing, prioritizing these patients: for

nasopharyngeal swabs immersed in 1 ml of transport media, ≥ 7.14 (95% CI: 7.07-7.22) $\log_{10}$

copies/ml corresponds to the top 20% of COVID-19 cases. Doing so may identify asymptomatic

and presymptomatic infections more efficiently, a key step towards mitigation as the pandemic

continues.

Materials and Methods

Systematic review. We undertook a systematic review and prospectively submitted the protocol

for registration on PROSPERO (registration number, CRD42020204637). Other than the title of

this study, we have followed PRISMA reporting guidelines (39). The systematic review was

conducted according to Cochrane methods guidance (40). In-depth details on the search strategy,

selection criteria, data collection and contributing studies are included in the *SI Appendix*,

Methods.

Calculation of rVLs from specimen measurements. In this study, viral concentrations in

respiratory specimens were denoted as specimen measurements, whereas viral concentrations in

the respiratory tract were denoted as rVLs. To determine rVLs, each collected quantitative

specimen measurement was converted to rVL based on the dilution factor. For example,

measurements from swabbed specimens (NPS and OPS) typically report the RNA concentration

in viral transport media. Based on the expected uptake volume for swabs (0.128 ± 0.031 ml,

mean $\pm$ SD) (41) or reported collection volume for expulsed fluid in the study (e.g., 0.5 to 1 ml)

along with the reported volume of transport media in the study (e.g., 1 ml), we calculated the

dilution factor for each respiratory specimen to estimate the rVL. If the diluent volume was not

reported, then the dilution factor was calculated assuming a volume of 1 ml (NPS and OPS), 2

ml (POS and ETA) or 3 ml (NPA) of transport media (42-44). Unless dilution was reported for

Spu specimens, we used the specimen measurement as the rVL (21). The non-reporting of

diluent volume was noted as an element increasing risk of bias in the hybrid JBI critical appraisal

checklist. Specimen measurements (based on instrumentation, calibration, procedures and

reagents) are not standardized. While the above procedures (including only quantitative

measurements after extraction as an inclusion criterion, considering assay detection limits and

correcting for specimen dilution) have considered many of these factors, non-standardization

remains an inherent limitation in the variability of specimen measurements.

Meta-regression of k and heterogeneity in rVL. To assess the relationship between k and

heterogeneity in rVL, we performed a univariate meta-regression ($\log k = a(SD) + b$, where a

is the slope for association and b is the intercept) between pooled estimates of k (based on

studies describing community transmission) for COVID-19 ($k = 0.409$) (12-14, 45-48), SARS (k

$= 0.165$) (15) and A(H1N1)pdm09 ($k = 8.155$) (16, 17) and the SD of the rVLs in contributing

studies. Since SD was the metric, we used a fixed-effects model. For weighting in the meta-

regression, we used the proportion of rVL samples from each study relative to the entire

systematic dataset ($W_i = n_i/n_{total}$). All calculations were performed in units of $\log_{10}$ copies/ml.

As the meta-regression used pooled estimates of k for each infection, it assumed that there was

no correlated bias to k across contributing studies. The limit of detection for qRT-PCR

instruments used in the included studies did not significantly affect the analysis of heterogeneity

in rVL, as these limits tended to be below the values found for specimens with low virus

concentrations. The meta-regression was conducted using all contributing studies and showed a

weak association. Meta-regression was also conducted using studies that had low risk of bias

according to the hybrid JBI critical appraisal checklist and showed a strong association. The *P*-

value for association was obtained using the meta-regression slope *t*-test for a, the effect

estimate.

Meta-analysis of rVLs. Based on the search design and composition of contributing studies, the

meta-analysis overall estimates were the expected SARS-CoV-2, SARS-CoV-1 and

A(H1N1)pdm09 rVL when encountering a COVID-19, SARS or A(H1N1)pdm09 case,

respectively, during their infectious period. Pooled estimates and 95% CIs for the expected rVL

of each virus across their infectious period were calculated using a random-effects meta-analysis

(DerSimonian and Laird method). The estimates for rVL assumed that each viral copy was

extracted and quantified from the tested specimen aliquot. For studies reporting summary

statistics in medians and interquartile or total ranges, we derived estimates of the mean and

variance and calculated the 95% CIs (49). All calculations were performed in units of $\log_{10}$

copies/ml. Between-study heterogeneity in meta-analysis was assessed using Cochran's Q test

and the I^2 and τ^2 statistics. If significant between-study heterogeneity in meta-analyses was

encountered, sensitivity analysis based on the risk of bias of contributing studies was performed.

The meta-analyses were conducted using STATA 14.2 (StataCorp LLC, College Station, Texas,

USA).

Age and symptomatology subgroup analyses of SARS-CoV-2 rVLs. The overall estimate for

each subgroup was the expected rVL when encountering a case of that subgroup during the

infectious period. Studies reporting data exclusively from a subgroup of interest were directly

included in the analysis after rVL estimations. For studies in which data for these subgroups

constituted only part of its dataset, rVLs from the subgroup were extracted to calculate the mean,

variance and 95% CIs. Random-effects meta-analysis was performed as described above. For

meta-analyses of pediatric and asymptomatic COVID-19 cases, contributing studies had low risk

of bias, and no risk-of-bias sensitivity analyses were performed for these subgroups.

Distributions of rVL. We pooled the entirety of individual sample data in the systematic dataset

by disease, COVID-19 subgroups and DFSO. For analyses of SARS-CoV-2 dynamics across

disease course, we included estimated rVLs from negative qRT-PCR measurements of

respiratory specimens for cases that had previously been quantitatively confirmed to have

COVID-19. These rVLs were estimated based on the reported assay detection limit in the

respective study. Probability plots and modified Kolmogorov–Smirnov tests used the Blom

scoring method and were used to determine the suitability of normal, lognormal, gamma and

Weibull distributions to describe the distribution of rVLs for SARS-CoV-2, SARS-CoV-1 and

A(H1N1)pdm09. For each virus, the data best conformed to Weibull distributions, which is

described by the probability density function

$$f(v) = \frac{\alpha}{\beta}\left(\frac{v}{\beta}\right)^{\alpha-1} e^{-(v/\beta)^\alpha}, \tag{1}$$

where α is the shape factor, β is the scale factor and v is rVL ($v \geq 0$ $\log_{10}$ copies/ml). Weibull

distributions were fitted on the entirety of collected individual sample data for the respective

category. Since individual specimen measurements could not be collected from all studies, there

was a small bias on the mean estimate for each fitted distribution. Thus, for the curves shown in

Fig. 4, *B* and *C*, the mean of the Weibull distributions summarized in *SI Appendix*, Table S7 was

adjusted to be the subgroup meta-analysis estimate for correction; the SD and distribution around

that mean remained consistent.

For each Weibull distribution, the value of the rVL at the xth percentile was determined

using the quantile function,

$$v_x = \beta[-\ln(1-x)]^{1/\alpha}. \tag{2}$$

For cp curves, we used eq. (2) to determine rVLs from the 1st cp to the 99th cp (step size, 1%).

Curve fitting to eq. (1) and calculation of eq. (2) and its 95% CI was performed using the

Distribution Fitter application in Matlab R2019b (MathWorks, Inc., Natick, Massachusetts,

USA).

Viral kinetics. To model SARS-CoV-2 kinetics during respiratory infection, we used a

mechanistic epithelial cell-limited model for the respiratory tract (50), based on the system of

differential equations:

423
$$\frac{dT}{dt} = -\beta TV \tag{3}$$

424
$$\frac{dI}{dt} = \beta TV - \delta I \tag{4}$$

425
$$\frac{dV}{dt} = pI - cV, \tag{5}$$

where T is the number of uninfected target cells, I is the number of productively infected cells, V

is the rVL, β is the infection rate constant, p is the rate at which airway epithelial cells shed virus

to the extracellular fluid, c is the clearance rate of virus and δ is the clearance rate of

productively infected cells. Parameter units are summarized in *SI Appendix*, Table S8. Using

these parameters, the viral half-life in the respiratory tract ($t_{1/2} = \ln 2/c$) and the half-life of

productively infected cells ($t_{1/2} = \ln 2/\delta$) could be estimated. Moreover, the cellular basic

reproductive number (the expected number of secondary infected cells from a single

productively infected cell placed in a population of susceptible cells) was calculated by

434
$$R_{0,c} = \frac{p\beta T_0}{c\delta}, \tag{6}$$

where T_0 is the initial number of susceptible cells (50). Further details on fitting procedure and

analyses of viral kinetics are included in the *SI Appendix*, Methods.

Likelihood of respiratory particles containing virions. To calculate an unbiased estimator for

viral partitioning (the expected number of viable copies in an expelled particle at a given size),

we multiplied rVLs with the volume equation for spherical particles during atomization and the

estimated viability proportion, according to the following equation:

$$\lambda = \frac{\pi \rho v_p \gamma \upsilon}{6} d^3,$$ (7)

where λ is the expectation value, ρ is the material density of the respiratory particle (997 g/m³),

v_p is the volumetric conversion factor (1 ml/g), γ is the viability proportion, υ is the rVL and d is

the hydrated diameter of the particle during atomization.

The model assumed γ was 0.1% as a population-level estimate. For influenza,

approximately 0.1% of copies in particles expelled from the respiratory tract represent viable

virus (51), which is equivalent to one in 3 $\log_{10}$ copies/ml for rVL or, after dilution in transport

media, roughly one in 4 $\log_{10}$ copies/ml for specimen concentration. Respiratory specimens taken

from influenza cases show positive cultures for specimen concentrations down to 4 $\log_{10}$

copies/ml (52). Likewise, for COVID-19 cases, recent reports also show culture-positive

respiratory specimens with SARS-CoV-2 concentrations down to 4 $\log_{10}$ copies/ml (21),

including from pediatric (53) and asymptomatic (22) cases. Our analyses indicated that SARS-

CoV-2 rVLs were not different at different sites in the respiratory tract. Moreover, replication-

competent SARS-CoV-2 has been found in respiratory specimens taken throughout the

respiratory tract (mouth, nasopharynx, oropharynx and lower respiratory tract) (21, 54). Taken

together, these considerations suggested that the assumption for viability proportion (0.1%) was

suitable to model the likelihood of respiratory particles containing viable SARS-CoV-2. In

accordance with the discussion above, the model did not differentiate this population-level

viability estimate based on age, symptomatology or sites of atomization. Based on the relative

relationship between the residence time of expelled particles before assessment (~5 s) (51), we

took the viability proportion (0.1%) to be for equilibrated particles.

Likelihood profiles were determined using Poisson statistics, as described by the probability

mass function

465
$$P(X = k) = \frac{\lambda^k e^{-\lambda}}{k!}, \tag{8}$$

466   where k is the number of virions partitioned within the particle. For λ, 95% CIs were determined

467   using the variance of its rVL estimate. To determine 95% CIs for likelihood profiles from the

468   probability mass function, we used the delta method, which specifies

469
$$\mathrm{Var}\big(g(\boldsymbol{\theta})\big) \approx \sigma^2 \dot{g}(\boldsymbol{\theta})' \mathbf{D} \dot{g}(\boldsymbol{\theta}), \tag{9}$$

470   where $\sigma^2 \mathbf{D}$ is the covariance matrix of $\boldsymbol{\theta}$ and $\dot{g}(\boldsymbol{\theta})$ is the gradient of $g(\boldsymbol{\theta})$. For the univariate

471   Poisson distribution, $\sigma^2 \mathbf{D} = \lambda$ and

472
$$\dot{g}(\theta) = \frac{\lambda^{k-1} e^{-\lambda}}{k!} (k - \lambda). \tag{10}$$

Rate profiles of particles expelled by respiratory activities. Distributions from the literature

were used to determine the rate profiles of particles expelled during respiratory activities. For

breathing, talking and coughing, we used data from Johnson et al (55). For singing, we used data

from Morawaska et al (56) for smaller aerosols (d_a < 20 µm) and used the profiles from talking

for larger aerosols and droplets based on the oral cavity mechanism from Johnson et al (55).

Further details on the calculation of rate profiles are included in the *SI Appendix*, Methods. We

compared these rate profiles with those collected from talking loudly and talking quietly from

Asadi et al (57). After dehydration, the particle diameter becomes approximately 0.5 times the

initial size from when atomized in the respiratory tract (55), which was used as the factor

between the diameter of hydrated particles during atomization and dehydrated particles.

Equilibrium aerodynamic diameter was calculated by $d_a = d_p(\rho/\rho_0)^{1/2}$, where d_p is the

dehydrated diameter, ρ is the material density of the respiratory particle (taken to be 1 g/cm^3

based on the composition of dehydrated respiratory particles) and ρ_0 is the reference material

density (1 g/cm^3). Curves based on discrete particle measurements were connected using the

nonparametric Akima spline function.

Shedding virions via respiratory droplets and aerosols. To model the respiratory shedding

rate across particle size, rVL estimates and the hydrated diameters of particles expelled by a

respiratory activity were input into eq. (7), and the output was then multiplied by the rate profile

of the activity (talking, singing, breathing or coughing). To assess the relative contribution of

aerosols and droplets to mediating respiratory viral shedding for a given respiratory activity, we

calculated the proportion of the cumulative hydrated volumetric rate contributed by buoyant

aerosols ($d_a \leq 10$ μm), long-range aerosols (10 μm $< d_a \leq 50$ μm), short-range aerosols (50 μm $<$

$d_a \leq 100$ μm) and droplets ($d_a > 10$ μm) for that respiratory activity. Since the Poisson mean was

proportional to cumulative volumetric rate, this estimate of the relative contribution of aerosols

and droplets to respiratory viral shedding was consistent among viruses and cps in the model.

To determine the total respiratory shedding rate for a given respiratory activity across cp, we

determined the cumulative hydrated volumetric rate (by summing the hydrated volumetric rates

across particle sizes for that respiratory activity) of particle atomization and input it into eq. (7).

Using rVLs and their variances as determined by the Weibull quantile functions, we then

calculated the Poisson means and their 95% CIs at the different cps.

To assess the influence of heterogeneity in rVL on individual infectiousness, we first

considered transmission of A(H1N1)pdm09 via aerosols (19). The 50% human infectious dose

(HID$_{50}$) of aerosolized A(H1N1)pdm09 was taken to be 1-3 virions (26). To determine the

expected time required for a A(H1N1)pdm09 case to shed 1 virion via aerosols, we took the

reciprocal of the Poisson means and their 95% CIs at the different cps of the estimated shedding

rates. The expected time required for a COVID-19 case to shed 1 virion via aerosols or 1 virion

via droplets or aerosols was determined in a same manner.

Data availability. Data will be made available upon request. All raw data, code and model

outputs from this study will be made publicly available in online repositories after peer review.

Search strategies for the systematic review are shown in Supplementary Tables 1-5. The

systematic review protocol was prospectively registered on PROSPERO (registration number,

CRD42020204637).

Acknowledgments

We thank T. Alba (Toronto) for discussion on statistical methods. We thank J. Jimenez

(Colorado) for discussion on the characteristics of aerosols and droplets. We thank E. Lavezzo

and A. Chrisanti (Padova) and A. Wyllie, A. Ko and N. Grubaugh (Yale) for responses to data

inquiries. This work was supported by the Natural Sciences and Engineering Research Council

of Canada (NSERC) and the Toronto COVID-19 Action Fund. P.Z.C. was supported by the

NSERC Vanier Scholarship (608544). D.N.F. was supported by the Canadian Institutes of Health

Research (Canadian COVID-19 Rapid Research Fund, OV4-170360). F.X.G. was supported by

the NSERC Senior Industrial Research Chair.

Author Contributions: P.Z.C. designed research, analyzed data and wrote the paper. P.Z.C. and

N.B. conducted screening, appraised studies and drafted the review protocol. Z.P. developed and

conducted the systematic review search. M.K. and D.N.F. assessed methods, interpreted results

and contributed to the discussion. All authors reviewed and revised the manuscript. F.X.G.

supervised the research.

Competing Interest Statement: The authors declare no competing interest.

References

1. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect. Dis.* **20**, 533-534 (2020).

2. K. A. Prather *et al.*, Airborne transmission of SARS-CoV-2. *Science* **370**, 303-304 (2020).

3. C. J. Roy, D. K. Milton, Airborne transmission of communicable infection — the elusive pathway. *N. Engl. J. Med.* **350**, 1710-1712 (2004).

4. L. Liu, Y. Li, P. V. Nielsen, J. Wei, R. L. Jensen, Short-range airborne transmission of expiratory droplets between two people. *Indoor Air* **27**, 452-462 (2017).

5. J. J. Wei, Y. G. Li, Enhanced spread of expiratory droplets by turbulence in a cough jet. *Build. Environ.* **93**, 86-96 (2015).

6. D. K. Chu *et al.*, Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* **395**, 1973-1987 (2020).

7. S. Y. Park *et al.*, Coronavirus disease outbreak in call center, South Korea. *Emerg. Infect. Dis.* **26**, 1666-1670 (2020).

8. J. Y. Lu *et al.*, COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020. *Emerg. Infect. Dis.* **26**, 1628-1631 (2020).

9. L. Hamner *et al.*, High SARS-CoV-2 attack rate following exposure at a choir practice - Skagit County, Washington, March 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 606-610 (2020).

10. Q. Li *et al.*, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N. Engl. J. Med.* **382**, 1199-1207 (2020).

11. X. Hao *et al.*, Reconstruction of the full transmission dynamics of COVID-19 in Wuhan.

Nature **584**, 420-424 (2020).

12. R. Laxminarayan *et al.*, Epidemiology and transmission dynamics of COVID-19 in two

Indian states. *Science* **370**, 691-697 (2020).

13. A. Endo, S. Abbott, A. J. Kucharski, S. Funk, Estimating the overdispersion in COVID-

19 transmission using outbreak sizes outside China. *Wellcome Open Research* **5** (2020).

14. Q. Bi *et al.*, Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their

close contacts in Shenzhen, China: a retrospective cohort study. *The Lancet Infectious*

Diseases **20**, 911-919 (2020).

15. J. O. Lloyd-Smith, S. J. Schreiber, P. E. Kopp, W. M. Getz, Superspreading and the effect

of individual variation on disease emergence. *Nature* **438**, 355-359 (2005).

16. M. G. Roberts, H. Nishiura, Early estimation of the reproduction number in the presence

of imported cases: pandemic influenza H1N1-2009 in New Zealand. *PLoS One* **6**, e17835

(2011).

17. J. Brugger, C. L. Althaus, Transmission of and susceptibility to seasonal influenza in

Switzerland from 2003 to 2015. *Epidemics* **30**, 100373 (2020).

18. I. T. Yu *et al.*, Evidence of airborne transmission of the severe acute respiratory

syndrome virus. *N. Engl. J. Med.* **350**, 1731-1739 (2004).

19. B. J. Cowling *et al.*, Aerosol transmission is an important mode of influenza A virus

spread. *Nature Communications* **4**, 1935 (2013).

20. E. C. Lee, N. I. Wada, M. K. Grabowski, E. S. Gurley, J. Lessler, The engines of SARS-

CoV-2 spread. *Science* **370**, 406-407 (2020).

21. R. Wolfel *et al.*, Virological assessment of hospitalized patients with COVID-2019.

Nature **581**, 465-469 (2020).

22. M. M. Arons *et al.*, Presymptomatic SARS-CoV-2 infections and transmission in a

skilled nursing facility. *N. Engl. J. Med.* **382**, 2081-2090 (2020).

23. X. He *et al.*, Temporal dynamics in viral shedding and transmissibility of COVID-19.

Nat. Med. **26**, 672-675 (2020).

24. V. E. Pitzer, G. M. Leung, M. Lipsitch, Estimating variability in the transmission of

severe acute respiratory syndrome to household contacts in Hong Kong, China. *Am. J.*

Epidemiol. **166**, 355-363 (2007).

25. D. K. Ip *et al.*, Viral shedding and transmission potential of asymptomatic and

paucisymptomatic influenza virus infections in the community. *Clin. Infect. Dis.* **64**, 736-

742 (2017).

26. P. Fabian *et al.*, Influenza virus in human exhaled breath: an observational study. *PLoS*

One **3**, e2691 (2008).

27. J. Ma *et al.*, COVID-19 patients in earlier stages exhaled millions of SARS-CoV-2 per

hour. *Clin. Infect. Dis.* 10.1093/cid/ciaa1283 (2020).

28. H. Y. Cheng *et al.*, Contact tracing assessment of COVID-19 transmission dynamics in

Taiwan and risk at different exposure periods before and after symptom onset. *JAMA*

Intern Med **180**, 1156-1163 (2020).

29. W. E. Wei *et al.*, Presymptomatic transmission of SARS-CoV-2 — Singapore, January

23-March 16, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 411-415 (2020).

30. Z. Du *et al.*, Serial interval of COVID-19 among publicly reported confirmed cases.

Emerg. Infect. Dis. **26**, 1341-1343 (2020).

31. W. J. Guan *et al.*, Clinical characteristics of coronavirus disease 2019 in China. *N. Engl.*

J. Med. **382**, 1708-1720 (2020).

32. R. Li *et al.*, Substantial undocumented infection facilitates the rapid dissemination of

novel coronavirus (SARS-CoV-2). *Science* **368**, 489-493 (2020).

33. L. Luo *et al.*, Contact settings and risk for transmission in 3410 close contacts of patients

with COVID-19 in Guangzhou, China: a prospective cohort study. *Ann. Intern. Med.*

10.7326/M20-2671 (2020).

34. X. Lu *et al.*, SARS-CoV-2 infection in children. *N. Engl. J. Med.* **382**, 1663-1665 (2020).

35. C. C.-R. Team, Coronavirus disease 2019 in children - United States, February 12-April

2, 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 422-426 (2020).

36. M. S. Han, J. H. Byun, Y. Cho, J. H. Rim, RT-PCR for SARS-CoV-2: quantitative versus

qualitative. *Lancet Infect. Dis.* 10.1016/S1473-3099(20)30424-2 (2020).

37. H.-L. Yen *et al.*, Effect of voicing and articulation manner on aerosol particle emission

during human speech. *PLoS One* **15** (2020).

38. J. J. A. van Kampen *et al.*, Shedding of infectious virus in hospitalized patients with

coronavirus disease-2019 (COVID-19): duration and key determinants.

medRxiv:10.1101/2020.06.08.20125310 (2020).

39. D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, P. Group, Preferred reporting items for

systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* **6**, e1000097

(2009).

40. J. P. T. Higgins *et al.* Cochrane handbook for systematic reviews of interventions. in

Cochrane book series (John Wiley & Sons, 2019).

41. P. Warnke, L. Warning, A. Podbielski, Some are more equal - a comparative study on

swab uptake and release of bacterial suspensions. *PLoS One* **9**, e102215 (2014).

42. E. Lavezzo *et al.*, Suppression of a SARS-CoV-2 outbreak in the Italian municipality of

Vo'. *Nature* **584**, 425-429 (2020).

43. K. K. To *et al.*, Temporal profiles of viral load in posterior oropharyngeal saliva samples

and serum antibody responses during infection by SARS-CoV-2: an observational cohort

study. *Lancet Infect. Dis.* **20**, 565-574 (2020).

44. L. L. Poon *et al.*, Detection of SARS coronavirus in patients with severe acute respiratory

syndrome by conventional and real-time quantitative reverse transcription-PCR assays.

Clin. Chem. **50**, 67-72 (2004).

45. D. C. Adam *et al.*, Clustering and superspreading potential of SARS-CoV-2 infections in

Hong Kong. *Nat. Med.* 10.1038/s41591-020-1092-0 (2020).

46. J. Riou, C. L. Althaus, Pattern of early human-to-human transmission of Wuhan 2019

novel coronavirus (2019-nCoV), December 2019 to January 2020. *Euro Surveill.* **25**

(2020).

47. Y. Zhang, Y. Li, L. Wang, M. Li, X. Zhou, Evaluating transmission heterogeneity and

super-spreading event of COVID-19 in a metropolis of China. *Int. J. Environ. Res. Public*

Health **17**, 3705 (2020).

48. A. Tariq *et al.*, Real-time monitoring the transmission potential of COVID-19 in

Singapore, March 2020. *BMC Med.* **18**, 166 (2020).

49. X. Wan, W. Wang, J. Liu, T. Tong, Estimating the sample mean and standard deviation

from the sample size, median, range and/or interquartile range. *BMC Med. Res. Methodol.*

14, 135 (2014).

50. P. Baccam, C. Beauchemin, C. A. Macken, F. G. Hayden, A. S. Perelson, Kinetics of

influenza A virus infection in humans. *J. Virol.* **80**, 7590-7599 (2006).

51. J. Yan *et al.*, Infectious virus in exhaled breath of symptomatic seasonal influenza cases

from a college community. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 1081-1086 (2018).

52. L. L. Lau *et al.*, Viral shedding and clinical illness in naturally acquired influenza virus

infections. *J. Infect. Dis.* **201**, 1509-1516 (2010).

53. A. G. L'Huillier, G. Torriani, F. Pigny, L. Kaiser, I. Eckerle, Culture-competent SARS-

CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. *Emerg.*

Infect. Dis. **26**, 2494-2497 (2020).

54. H. W. Jeong *et al.*, Viable SARS-CoV-2 in various specimens from COVID-19 patients.

Clin. Microbiol. Infect. 10.1016/j.cmi.2020.07.020 (2020).

55. G. R. Johnson *et al.*, Modality of human expired aerosol size distributions. *J. Aerosol Sci*

42, 839-851 (2011).

56. L. Morawska *et al.*, Size distribution and sites of origin of droplets expelled from the

human respiratory tract during expiratory activities. *J. Aerosol Sci* **40**, 256-269 (2009).

57. S. Asadi *et al.*, Aerosol emission and superemission during human speech increase with

voice loudness. *Sci. Rep.* **9**, 2348 (2019).

Figures

Fig. 1. Development of the systematic dataset.

Fig. 2. Association of overdispersion in SARS-CoV-2, SARS-CoV-1 and A(H1N1)pdm09

transmissibility with heterogeneity in rVL. Meta-regression of dispersion parameter (k) with the

standard deviation (SD) of respiratory viral loads (rVLs) from contributing studies with low risk

of bias (Pearson's r = -0.73). Pooled estimates of k were determined from the literature for each

infection. Blue, red and yellow circles denote A(H1N1)pdm09 (N = 22), COVID-19 (N = 24)

and SARS (N = 7) studies, respectively. Circle sizes denote weighting in the meta-regression.

The P-value was obtained using the meta-regression slope t-test.

Subgroup, study ref.	Cases No.	Type	Specimens No.	DFSO	Type	Respiratory viral load, $\log_{10}$ copies/ml (95% CI)	P value for difference
Adult COVID-19							
62	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
42	100	H, C, A, S, Ps, As	106	-2 to 10	NPS, OPS	4.65 (4.35-4.95)	
63	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
43	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
64	14	H, A, S, As	55	0 to 10	NPS, OPS	5.30 (4.87-5.74)	
65	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
66	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
67	2,182	C, A, As	2,182	0	NPS	6.01 (5.93-6.09)	
68	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
69	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
21	9	H, A, S, As	133	2 to 10	NPS, OPS, Spu	6.21 (5.90-6.52)	
70	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
71	5	H, A, S	5	7 to 9	NPS	6.38 (5.16-7.60)	
72	-	H, A, S, As	38	0 to 9	NPA, NPS, OPS, Spu	6.52 (5.77-7.27)	
73	39	H, A, S, As	41	0 to 10	NPS	6.71 (6.20-7.23)	
74	347	H, A, S	347	0 to 5	NPS	6.97 (6.77-7.18)	
75	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
76	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
38	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
77	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
78	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall ($Q_{20} > 100$, $P < 0.001$, $I^2 = 97.7\%$)						6.33 (5.95-6.70)	-
Pediatric COVID-19							
42	2	H, C, P, S	3	8 to 9	NPS, OPS	3.77 (1.74-5.81)	
79	14	H, P, S	14	0 to 10	NPS	5.59 (4.31-6.87)	
80	7	H, P, S, Ps, As	14	-1 to 10	NPS	5.69 (5.26-6.12)	
81	54	C, P, S, Ps, As	54	-3 to 10	NPS	5.82 (5.36-6.29)	
74	58	H, P, S	58	0 to 5	NPS	6.97 (6.45-7.49)	
53	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
82	12	H, P, S, As	27	0 to 10	NPS	8.07 (7.47-8.67)	
Overall ($Q_6 = 20.5$, $P = 0.002$, $I^2 = 79.7\%$)						6.29 (5.27-7.32)	0.476
Symptomatic/presymptomatic COVID-19							
62	4	H, A, S	9	4 to 10	NPS, OPS	4.12 (3.18-5.05)	
42	53	H, C, A, P, S, Ps	60	-2 to 10	NPS, OPS	4.43 (4.03-4.84)	
63	6	H, A, S	6	3 to 8	OPS	5.13 (4.83-5.42)	
64	13	H, A, S	51	0 to 10	NPS, OPS	5.25 (4.79-5.71)	
83	77	H, S, Ps	119	-1 to 8	OPS, Spu	5.26 (4.63-5.90)	
43	23	H, A, S	51	0 to 10	ETA, POS	5.29 (4.65-5.93)	
65	-	H, N, A, S	31	2 to 10	NPS, OPS, Spu	5.41 (4.81-6.01)	
79	17	H, A, P, S	17	0 to 10	NPS	5.53 (4.36-6.71)	
66	-	H, A, S	19	1 to 10	POS, Spu	5.62 (5.22-6.03)	
80	6	H, P, S, Ps	13	-1 to 10	NPS	5.77 (5.10-6.53)	
81	81	C, A, P, S, Ps	81	-3 to 10	NPS	5.78 (5.41-6.15)	
21	8	H, A, S	129	2 to 10	NPS, OPS, Spu	5.88 (5.60-6.17)	
68	171	N, A, S	171	0 to 10	NPS	6.07 (5.79-6.34)	
69	103	H, N, A, S	103	0 to 8	NPS, OPS	6.10 (5.98-6.23)	
70	41	H, A, S	310	2 to 10	NPS, OPS, POS	6.28 (6.05-6.50)	
71	5	H, A, S	5	7 to 9	NPS	6.38 (5.16-7.60)	
73	31	H, A, P, S	33	2 to 10	NPS	6.95 (6.37-7.53)	
74	405	H, A, P, S	405	0 to 5	NPS	6.95 (6.78-7.17)	
53	23	H, P, S	23	0 to 4	NPS	7.20 (6.23-8.16)	
75	24	H, A, S	33	0 to 10	NPS	7.51 (6.97-8.05)	
76	205	H, N, A, S	205	0 to 10	NPS	7.55 (7.30-7.81)	
38	-	H, A, S	154	0 to 10	NPS, Spu	7.83 (7.58-8.08)	
84	2	H, A, P, S	8	4 to 10	NPS, OPS, Spu	7.91 (6.69-9.12)	
77	148	N, A, S	296	1 to 8	NPS	8.04 (7.81-8.28)	
82	9	H, P, S	20	0 to 10	NPS	8.10 (7.37-8.33)	
78	5	H, A, S	63	0 to 10	NPS, OPS	8.34 (7.95-8.73)	
Overall ($Q_{25} > 100$, $P < 0.001$, $I^2 = 91.1\%$)						6.37 (5.93-6.80)	-
Asymptomatic COVID-19							
42	49	H, C, A, As	49	0	NPS, OPS	4.89 (4.46-5.33)	
81	52	C, A, P, As	52	0	NPS	5.31 (4.85-5.77)	
73	9	H, A, As	9	0	NPS	5.67 (4.92-6.43)	
67	2,200	C, A, P, As	2,200	0	NPS	6.01 (5.93-6.09)	
82	3	H, P, As	7	0 to 8	NPS	8.01 (6.91-9.11)	
Overall ($Q_4 = 47.1$, $P < 0.001$, $I^2 = 91.5\%$)						5.84 (5.19-6.50)	0.090

Fig. 3. Subgroup analyses of SARS-CoV-2 rVL during the infectious period. Random-effects

meta-analyses comparing the expected respiratory viral loads (rVLs) of adult (≥18 years old)

COVID-19 cases with pediatric (<18 years old) ones (top) and symptomatic/presymptomatic

infections with asymptomatic ones (bottom) during the infectious period. Quantitative rVLs refer

to virus concentrations in the respiratory tract. Case types: hospitalized (H), not admitted (N),

community (C), adult (A), pediatric (P), symptomatic (S), presymptomatic (Ps) and

asymptomatic (As). Specimen types: endotracheal aspirate (ETA), nasopharyngeal aspirate

(NPA), nasopharyngeal swab (NPS), oropharyngeal swab (OPS), posterior oropharyngeal saliva

(POS) and sputum (Spu). Dashes denote case numbers that were not obtained. Box sizes denote

weighting in the overall estimates. Between-study heterogeneity was assessed using the P-value

from Cochran's Q test and the I^2 statistic. References after 57 are listed in *SI Appendix*,

References. One-sided Welch's t-tests compared expected rVLs between the COVID-19

subgroups (non-significance, $P > 0.05$).

Fig. 4. Heterogeneity and kinetics of SARS-CoV-2 rVL. (*A*) Estimated distribution of

respiratory viral load (rVL) for SARS-CoV-2 ($N = 3{,}834$ samples from $N = 26$ studies) and

A(H1N1)pdm09 ($N = 512$ samples from $N = 10$ studies) throughout the infectious periods. (*B*

and *C*) Estimated distribution of SARS-CoV-2 rVL for adult ($N = 3{,}575$ samples from $N = 20$

studies) and pediatric ($N = 198$ samples from $N = 9$ studies) (*B*) and

symptomatic/presymptomatic ($N = 1{,}574$ samples from $N = 22$ studies) and asymptomatic ($N =$

$2{,}221$ samples from $N = 7$ studies) (*C*) COVID-19 cases. (*D*) SARS-CoV-2 rVLs fitted to a

mechanistic model of viral kinetics (black curve, $r^2 = 0.84$ for mean estimates). Filled circles and

bars depict mean estimates and 95% CIs. Open circles show the entirety of individual sample

data over days from symptom onset (DFSO) (left to right, $N = 3, 15, 50, 63, 71, 75, 85, 93, 105,$

$136, 123, 128$ and 115 samples from $N = 21$ studies). (*E*) Estimated distributions of SARS-CoV-

2 rVL across DFSO. Weibull distributions were fitted on the entirety of individual sample data

709   for the virus, subgroup or DFSO in the systematic dataset. Arrows denote 90th case percentiles

710   for SARS-CoV-2 rVL distributions.

Fig. 5. Heterogeneity in shedding SARS-CoV-2 via droplets and aerosols. (*A* and *B*) Estimated

likelihood of respiratory particles containing viable SARS-CoV-2 when expelled by the mean

(top) or 98th case percentile (cp) (bottom) COVID-19 cases at -1 (*A*) or 1 (*B*) days from symptom

onset (DFSO). For higher no. of virions, some likelihood curves were omitted to aid

visualization. When the likelihood for 0 virions approaches 0%, particles are expected to contain

at least one viable copy. (*C* to *F*) Rate that the mean and 98th-cp COVID-19 cases at 1 DFSO

shed viable SARS-CoV-2 by talking, singing, breathing or coughing over particle size. (*G*)

Relative contributions of droplets and aerosols to shedding virions for each respiratory activity

(left). Relative contribution of buoyant, long-range and short-range aerosols to shedding virions

via aerosols for each respiratory activity (right). (*H*) Case heterogeneity in the total shedding rate

(over all particle sizes) of virions via singing across the infectious period. Earlier

presymptomatic days were excluded based on limited data. Data range between the 1st and 99th

cps. Lines and bands represent estimates and 95% CIs, respectively, for estimated likelihoods or

Poisson means.